The report presents a summary of the reimbursement situation for occipital nerve stimulation in Europe. The following indications are considered: migraine with aura; cluster headache syndrome. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

The report presents a summary of the reimbursement situation for mechanical ventilation in Europe. The following clinical indications are considered: acute community-acquired viral pneumonia complicated with acute respiratory failure; severe sepsis due to acute community-acquired viral pneumonia with multiorgan failure (cardiac, respiratory and renal); acute hemorrhagic stroke with the development of com. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

In February 2020, the Andalusian Health Technology Assessment Department published an assessment report on the evaluation of effectiveness and safety of epicardial closure of left atrial appendage using clips by minimally invasive surgery for thromboembolism prevention in patients with atrial fibrillation. The scientific evidence about the effectiveness and safety of the left atrial appendage closure through minimally invasive epicardial clipping is inadequate and insufficient; further research is needed.

The report presents a summary of the reimbursement situation for the use of negative pressure wound therapy (NPWT) (procedure and medical aid) in Europe. The following clinical indications are considered: diabetic foot ulcer; venous leg ulcer; pressure ulcer. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) has introduced two new service codes for physicians’ teleconsultation regarding COVID-19. INAMI Insurance Committee established a reimbursement fee of €20.

On 22 January 2020, the consultation on proposals for a national tariff for 2020/21 closed. However, the release of the 2020/21 tariff has been postponed due to the NHS response to COVID-19. NHS will report publishing details at the earliest opportunity.

On March 4, 2020, the List of Analyses (AL/EA) and the Services Ordinance (KLV/OPre) were updated in Switzerland. On April 1, 2020, the KLV/OPre, the AL/EA, and the List of Medical Aids (MiGel/EMAp) will be updated in Switzerland.

In March 2020, Swedish Skåne Region has released a report for the use of hydrogel spacer in radiotherapy of prostate cancer. Treatment with hydrogel spacer provides long-term improved quality of life, but the scientific base is limited. The scientific evidence base on the positive effect of the spacer in erectile function is insufficient.

On March 13, 2020, the Institute for Quality and Efficiency in Health Care (IQWiG) announced that the new HTA reports would concern cystitis, heart disease in children, social isolation, as well as vitamin B12 / vitamin D deficiency in the elderly, and the Feldenkrais Method in treatment of mobility disorders.

In February 2020, the Andalusian Health Technology Assessment Department published an assessment report on the evaluation of validity, clinical utility, and safety of the next-generation sequencing genomic platform FoundationOne® in non-small cell lung cancer and other solid tumors. It was observed that it is necessary to carry out new studies to confirm the diagnostic results and the clinical usefulness of the test due to the low quality of existing evidence.

NHSX is creating a Digital Health Technology Standard to enhance the way the NHS assesses digital technology for use by patients and staff. It is meant to help developers understand what is required of them, and simplify and streamline how health technologies are assessed and commissioned for use in the NHS. The consultation continues until 22 April 2020 Wednesday.

A syndicated 105-page report includes information on the current administrative framework for health apps, current reimbursement framework, examples of reimbursed apps, the role of health technology assessment, upcoming changes in the reimbursement systems. The report includes analysis in five European countries: Belgium, England, France, Germany, and the Netherlands.